Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 15/20 | 0.44 |
| ▸ | HRH1 | P35367 | 15/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | FPR3 | P25089 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25499345 | 0.84 | HRH2 (0.42) | HRH2HRH1OPRK1HRH3FPR3 | |
| SCHEMBL25499344 | 0.80 | HRH2 (0.43) | HRH2HRH1OPRK1HRH3FPR3 | |
| SCHEMBL25499365 | 0.79 | HRH2 (0.41) | HRH2HRH1OPRK1HRH3FPR3 | |
| SCHEMBL25499378 | 0.79 | HRH2 (0.47) | HRH2HRH1OPRK1 | |
| SCHEMBL25499367 | 0.76 | HRH2 (0.41) | HRH2HRH1OPRK1HRH3 | |
| SCHEMBL22848877 | 0.76 | HRH2 (0.44) | HRH2HRH1HRH3FPR3FPR2 | |
| SCHEMBL24373154 | 0.75 | HRH2 (0.43) | HRH2HRH1OPRK1HRH3FPR3 | |
| SCHEMBL25499380 | 0.75 | HRH2 (0.47) | HRH2HRH1OPRK1 | |
| SCHEMBL25499353 | 0.74 | HRH2 (0.37) | HRH2HRH1OPRK1HRH3FPR3 | |
| SCHEMBL28795452 | 0.74 | HRH2 (0.54) | HRH2HRH1OPRK1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739076-B2 | Compound or its salt thereof targeting fibroblast activation protein, its preparation methods and its uses thereof | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, R.O.C. (TW) | 2023-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739076-B2 | Compound or its salt thereof targeting fibroblast activation protein, its preparation methods and its uses thereof | FIBP, FGFR2, FGFR1 | HRH2 3821/4885HRH1 2968/4885OPRK1 4802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.